A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women

Theodore V. Cooper, Robert Klesges, Margaret W. Debon, Susan M. Zbikowski, Karen Johnson, Linda H. Clemens

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

With smoking prevalence rates beginning to decline, studies designed to promote cessation in more challenging populations, like weight-concerned smokers, warrant attention. This study assessed the efficacy of two forms of pharmacotherapy [nicotine and phenylpropanolamine (PPA) gums] in addition to a 13-week cognitive behavioral smoking cessation program targeted for women. Participants were 439 females who met rigorous screening criteria and were randomized to one of the three treatment intervention groups (PPA gum, nicotine gum, or placebo gum). All participants attended a 13-week cognitive behavioral smoking cessation program and were given specific instructions on gum chewing. At posttest (13 weeks), and 6- and 12-month follow-ups, body weight and point prevalence abstinence were assessed. Analyses to determine potential differences between treatment groups on weight change and cessation rates were performed. Results indicated that neither change in body weight nor cessation rates significantly differed between groups. Attendance to sessions did appear to consistently increase the likelihood of quitting smoking at posttest and at each of the follow-ups. These results suggest that although the pharmacological interventions had no effect on cessation rates and postcessation weight gain, the behavioral component of the intervention was effective in increasing the odds of quitting smoking in weight-concerned women. Future efforts should focus on increasing adherence to behavioral program components, particularly session attendance.

Original languageEnglish (US)
Pages (from-to)61-75
Number of pages15
JournalAddictive Behaviors
Volume30
Issue number1
DOIs
StatePublished - Jan 1 2005

Fingerprint

Phenylpropanolamine
Gingiva
Nicotine
Weight Gain
Randomized Controlled Trials
Smoking
Placebos
Mastication
Smoking Cessation
Drug therapy
Weights and Measures
Chewing Gum
Screening
Body Weight Changes
Body Weight
Pharmacology
Drug Therapy
Therapeutics
Population

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Clinical Psychology
  • Toxicology
  • Psychiatry and Mental health

Cite this

A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women. / Cooper, Theodore V.; Klesges, Robert; Debon, Margaret W.; Zbikowski, Susan M.; Johnson, Karen; Clemens, Linda H.

In: Addictive Behaviors, Vol. 30, No. 1, 01.01.2005, p. 61-75.

Research output: Contribution to journalArticle

Cooper, Theodore V. ; Klesges, Robert ; Debon, Margaret W. ; Zbikowski, Susan M. ; Johnson, Karen ; Clemens, Linda H. / A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women. In: Addictive Behaviors. 2005 ; Vol. 30, No. 1. pp. 61-75.
@article{daf1f6d98ba643d0a98a761c588f8aa7,
title = "A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women",
abstract = "With smoking prevalence rates beginning to decline, studies designed to promote cessation in more challenging populations, like weight-concerned smokers, warrant attention. This study assessed the efficacy of two forms of pharmacotherapy [nicotine and phenylpropanolamine (PPA) gums] in addition to a 13-week cognitive behavioral smoking cessation program targeted for women. Participants were 439 females who met rigorous screening criteria and were randomized to one of the three treatment intervention groups (PPA gum, nicotine gum, or placebo gum). All participants attended a 13-week cognitive behavioral smoking cessation program and were given specific instructions on gum chewing. At posttest (13 weeks), and 6- and 12-month follow-ups, body weight and point prevalence abstinence were assessed. Analyses to determine potential differences between treatment groups on weight change and cessation rates were performed. Results indicated that neither change in body weight nor cessation rates significantly differed between groups. Attendance to sessions did appear to consistently increase the likelihood of quitting smoking at posttest and at each of the follow-ups. These results suggest that although the pharmacological interventions had no effect on cessation rates and postcessation weight gain, the behavioral component of the intervention was effective in increasing the odds of quitting smoking in weight-concerned women. Future efforts should focus on increasing adherence to behavioral program components, particularly session attendance.",
author = "Cooper, {Theodore V.} and Robert Klesges and Debon, {Margaret W.} and Zbikowski, {Susan M.} and Karen Johnson and Clemens, {Linda H.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1016/j.addbeh.2004.04.013",
language = "English (US)",
volume = "30",
pages = "61--75",
journal = "Addictive Behaviors",
issn = "0306-4603",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women

AU - Cooper, Theodore V.

AU - Klesges, Robert

AU - Debon, Margaret W.

AU - Zbikowski, Susan M.

AU - Johnson, Karen

AU - Clemens, Linda H.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - With smoking prevalence rates beginning to decline, studies designed to promote cessation in more challenging populations, like weight-concerned smokers, warrant attention. This study assessed the efficacy of two forms of pharmacotherapy [nicotine and phenylpropanolamine (PPA) gums] in addition to a 13-week cognitive behavioral smoking cessation program targeted for women. Participants were 439 females who met rigorous screening criteria and were randomized to one of the three treatment intervention groups (PPA gum, nicotine gum, or placebo gum). All participants attended a 13-week cognitive behavioral smoking cessation program and were given specific instructions on gum chewing. At posttest (13 weeks), and 6- and 12-month follow-ups, body weight and point prevalence abstinence were assessed. Analyses to determine potential differences between treatment groups on weight change and cessation rates were performed. Results indicated that neither change in body weight nor cessation rates significantly differed between groups. Attendance to sessions did appear to consistently increase the likelihood of quitting smoking at posttest and at each of the follow-ups. These results suggest that although the pharmacological interventions had no effect on cessation rates and postcessation weight gain, the behavioral component of the intervention was effective in increasing the odds of quitting smoking in weight-concerned women. Future efforts should focus on increasing adherence to behavioral program components, particularly session attendance.

AB - With smoking prevalence rates beginning to decline, studies designed to promote cessation in more challenging populations, like weight-concerned smokers, warrant attention. This study assessed the efficacy of two forms of pharmacotherapy [nicotine and phenylpropanolamine (PPA) gums] in addition to a 13-week cognitive behavioral smoking cessation program targeted for women. Participants were 439 females who met rigorous screening criteria and were randomized to one of the three treatment intervention groups (PPA gum, nicotine gum, or placebo gum). All participants attended a 13-week cognitive behavioral smoking cessation program and were given specific instructions on gum chewing. At posttest (13 weeks), and 6- and 12-month follow-ups, body weight and point prevalence abstinence were assessed. Analyses to determine potential differences between treatment groups on weight change and cessation rates were performed. Results indicated that neither change in body weight nor cessation rates significantly differed between groups. Attendance to sessions did appear to consistently increase the likelihood of quitting smoking at posttest and at each of the follow-ups. These results suggest that although the pharmacological interventions had no effect on cessation rates and postcessation weight gain, the behavioral component of the intervention was effective in increasing the odds of quitting smoking in weight-concerned women. Future efforts should focus on increasing adherence to behavioral program components, particularly session attendance.

UR - http://www.scopus.com/inward/record.url?scp=9244257882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9244257882&partnerID=8YFLogxK

U2 - 10.1016/j.addbeh.2004.04.013

DO - 10.1016/j.addbeh.2004.04.013

M3 - Article

VL - 30

SP - 61

EP - 75

JO - Addictive Behaviors

JF - Addictive Behaviors

SN - 0306-4603

IS - 1

ER -